# OnCo record ras-wild-type (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/ras-wild-type/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "ras-wild-type" ;
  schema:name "RAS wild-type (extended KRAS and NRAS testing)"@en ;
  schema:alternateName "RAS wild-type"@en, "RAS wild type"@en, "KRAS wild-type"@en, "KRAS wild type"@en, "wild-type RAS"@en, "extended RAS"@en, "extended RAS testing"@en, "RAS/BRAF wild-type"@en, "pan-RAS wild-type"@en, "RAS-WT"@en ;
  schema:description "RAS wild-type is the absence of a mutation, and it is the result that decides whether the EGFR antibodies cetuximab and panitumumab can be given in bowel cancer. Extended testing means KRAS and NRAS exons 2, 3 and 4, not just codons 12 and 13."@en ;
  schema:url <https://onco.cc/biomarkers/ras-wild-type/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools>, <https://doi.org/10.1056/NEJMoa1305275> ;
  onco:tag "biomarker", "kras", "negative-selector" ;
  onco:related <https://onco.cc/biomarkers/kras-g12d/>, <https://onco.cc/biomarkers/kras-g12c/>, <https://onco.cc/biomarkers/braf-v600e/> ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/rectal-cancer/>, <https://onco.cc/cancers/colon-cancer/>, <https://onco.cc/cancers/her2-amplified-colorectal/>, <https://onco.cc/cancers/braf-v600e-colorectal/> ;
  onco:technologies <https://onco.cc/technologies/companion-diagnostic/> ;
  onco:drugs <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/panitumumab/>, <https://onco.cc/drugs/encorafenib/>, <https://onco.cc/drugs/tucatinib/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/adagrasib/>, <https://onco.cc/drugs/therascreen-cdx/>, <https://onco.cc/drugs/tempus-xt-cdx/>, <https://onco.cc/drugs/foundationone-cdx/>, <https://onco.cc/drugs/caris-mi-cancer-seek/> ;
  onco:terms <https://onco.cc/terms/wild-type/>, <https://onco.cc/terms/extended-ras-testing/>, <https://onco.cc/terms/sidedness/>, <https://onco.cc/terms/ngs/> ;
  onco:trials <https://onco.cc/trials/prime/>, <https://onco.cc/trials/paradigm/>, <https://onco.cc/trials/crystal-fire3/>, <https://onco.cc/trials/calgb-80405/>, <https://onco.cc/trials/opus/>, <https://onco.cc/trials/codebreak-300/>, <https://onco.cc/trials/mountaineer/> .